Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cor Therapeutics Inc. (CORR) -- Ignore unavailable to you. Want to Upgrade?

To: Jacques Tenzel who wrote (372)	2/8/1999 9:40:00 PM
From: aknahow	Respond to of 712

Thanks, sorry there was nothing new. Competition in stroke area: infobeat.com

To: Jacques Tenzel who wrote (372)	2/10/1999 11:29:00 AM
From: aknahow	Respond to of 712

New patent. I do not pretend to understand the implications of this patent. Also realize that a patent is one thing and a marketable product is another. But, I like to see a company have a regular stream of new patents, and wonder what is going on when there are none for months at a time. United States Patent 5,866,681 Scarborough Feb. 2, 1999 Thrombin receptor antagonists Abstract Peptide derivatives serving as thrombin receptor antagonists are disclosed, which bear specificity for the cellular thrombin receptor without interfering with the catalytic activities of thrombin. The derivatives generally have the formula ##STR1## in which R(^1) and R(^3) are amide linkages, N-alkylamide linkages, or isosteric replacements of such linkages; R(^2) is either a neutral amino acid side chain or a hydrophobic radical; R(^4) is hydrophobic radical; R(^5) is CO, CH(2) or SO; X is either of the formula: ##STR2## in which R(^6) and R(^7) are H, alkyl, cycloalkylalkyl, alkoxyalkyl, alkylthioalkyl or arylalkyl, and R(^8) is a hydrophobic radical, or a hydrophobic residue; Y is alkoxy, hydroxy, amino, alkylamino, dialkylamino, in which any of the alkyl groups may be substituted with a basic moiety; Z is an amino acid or peptide residue; and m is zero or one.

To: Jacques Tenzel who wrote (372)	2/11/1999 10:49:00 AM
From: aknahow	Respond to of 712

Consensus estimate for current fiscal year ( 12/99 ) : $ -0.82 per share Consensus estimate for next fiscal year ( 12/0 ) : $ 0.21 per share Consensus estimate for current quarter ( /99) : $ -0.39 per share Last quarter's actual earnings :$ -0.63 per share Last quarter's EPS Surprise: -2 % Think the surprise data is wrong but that's old news. Posting anyway.<g> This is cut and paste, not my opinion nor my own errors which I reserve for my own original post.

To: Jacques Tenzel who wrote (372)	2/14/1999 9:33:00 PM
From: aknahow	Read Replies (2) \| Respond to of 712

Another filing. Was not aware this was necessary for less than 55 but here it is. Also is amended 13G so again this might not be anything new. "Capital Research and Management Company, an investment adviser registered under Section 203 of the Investment Advisers Act of 1940 is deemed to be the beneficial owner of 947,300 shares or 3.9% of the 24,319,000 shares of Common Stock believed to be outstanding as a result of acting as investment adviser to various investment companies registered under Section 8 of the Investment Company Act of 1940."